setmelanotide

Sponsor Rhythm Pharmaceuticals, INC. · listed as RYTM

READOUT Phase 3 Confidence: medium Source: clinicaltrials

Next catalyst

Event typeREADOUT

Expected date2027-03-13

As disclosedMar 13, 2027

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06760546

PhasePHASE3

StatusRECRUITING

Lead sponsorRhythm Pharmaceuticals, Inc.

Listed asRYTM

Condition(s)Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia; Optic Nerve Hypoplasia; Childhood-onset Combined Pituitary Horm…

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More RYTM catalysts